Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

NCT ID: NCT00634660

Last Updated: 2017-02-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31
• Study Completion Date: 2009-10-31

Brief Summary

The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.

Detailed Description

This is a Phase 1, open-label, single-dose study in approximately 35 subjects with PKU who are 16 to 50 years old. Seven cohorts are planned, each consisting of 5 subjects; the cohorts as planned are 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. Increasing doses of rAvPAL-PEG will be assessed sequentially until the final dose is evaluated or any of the stopping criteria are reached. Subjects will each receive a single dose and then will be followed for a total of 42 days (6 weeks) with visits to the clinical research unit (CRU) as specified in the Schedule of Events Toxicity will be measured according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v 3).

Conditions

Phenylketonuria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

0.001 mg/kg

One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

0.003 mg/kg

One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

0.01 mg/kg

One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

0.03 mg/kg

One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

0.1 mg/kg

One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

0.3 mg/kg

One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

1.0 mg/kg

One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.

Group Type: ACTIVE_COMPARATOR

rAvPAL-PEG

Intervention Type: DRUG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Interventions

rAvPAL-PEG

rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of PKU with both of the following:
• Current blood Phe concentration of ≥600 µmol/L at Screening.
• Average blood Phe concentration of ≥600 µmol/L over the past 3 years, using available data.
• Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
• Willing and able to comply with all study procedures.
• Between the ages of 16 and 50 years, inclusive.
• Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
• Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
• Stable diet with no significant modifications during the 4 weeks preceding the administration of study drug.
• In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening.

Exclusion Criteria

• Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
• Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
• Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
• Any condition that, in the view of the Principal Investigator (PI), places the subject at high risk of poor treatment compliance or of not completing the study.
• Known hypersensitivity to rAvPAL PEG or its excipients.
• Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal.
• Creatinine above the upper limit of normal.
• Donation of blood or plasma within 30 days prior to the administration of study drug.
• Use of any over-the-counter (OTC) medication, including vitamins, within 7 days prior to the administration of study drug, without evaluation and approval by the Investigator.
• Use of any prescription medication within 14 days prior to the administration of study drug without evaluation and approval by the Investigator.
• Treatment with any drug known to affect hepatic enzyme activity, including (but not limited to) barbiturates, phenothiazines, cimetidine, or carbamazepine, within 30 days prior to study drug administration.
• Use of any tobacco products within 60 days prior to study drug administration.
• Positive urine screen for use of nicotine (cotinine) or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, and opiates).
• Positive test or has been treated for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioMarin Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Celeste Decker, MD

Role: STUDY_DIRECTOR

BioMarin Pharmaceutical

Locations

Children's Memorial Hospital

Chicago, Illinois, United States

University of Minnesota Medical Center-Fairview

Minneapolis, Minnesota, United States

Washington University Center for Applied Research Sciences

St Louis, Missouri, United States

Mount Sinai Medical Center

New York, New York, United States

Oregon Health & Science University

Portland, Oregon, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

University of Utah Hospital

Salt Lake City, Utah, United States

University of Wisconsin

Madison, Wisconsin, United States

Countries

United States

Other Identifiers

PAL-001

Identifier Type: -

Identifier Source: org_study_id